Tacrolimus is one of the mainstay medications for renal transplantation patients. Vision loss is a rare but serious adverse effect associated with tacrolimus use. Herein, we report a male patient who developed acute vision loss during hospitalization for slow kidney graft function post-renal transplantation and 19 days after starting tacrolimus. The vision loss was associated with a recent rise in tacrolimus levels that required dose adjustment. The workup excluded cortical blindness and showed evidence of a newly developed bilateral central white cloudy inner retinal opacification resembling a cherry red spot on fundus examination. Tacrolimus toxicity was suspected, and the medication was replaced with cyclosporin. Follow-up was remarkable for mild improvement in the patient's vision and disappearance of structural changes on fundoscopy in both eyes. These findings are in keeping with a diagnosis of ischemic maculopathy. This is the first case of bilateral severe early-onset tacrolimus-associated ischemic maculopathy. According to our workup, this disease can be explained by a vasoocclusive accident at the arteriolar and venular level of the ciliomacular vascular system.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506439 | PMC |
http://dx.doi.org/10.7759/cureus.70157 | DOI Listing |
BMC Ophthalmol
January 2025
Department of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, Bengaluru, Karnataka, 560010, India.
Background: Accurate localization of premacular hemorrhages (PMHs) is crucial as treatment strategies vary significantly based on whether the hemorrhage resides within the vitreous gel, subhyaloid space, or beneath the internal limiting membrane (ILM). This report outlines the clinical features, diagnostic findings, and treatment outcomes in a patient diagnosed with a PMH secondary to suspected Valsalva retinopathy.
Methods: This is a retrospective interventional case report.
J Photochem Photobiol B
December 2024
Anne Bates Leach Eye Center, Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, United States of America; Ocular Microbiology Laboratory, Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, United States of America.
Introduction: Fungal keratitis is a leading cause of corneal blindness, with current antifungal treatments having limited efficacy. One promising treatment modality is Rose Bengal (RB) photodynamic antimicrobial therapy (PDAT) that has shown mixed success against fungal keratitis. Therefore, there is a need to explore the antimicrobial efficacy of other green-light activated photosensitizers that have deep penetration in the cornea to combat the deep fungal infections, such as Erythrosin B (EB) and Eosin Y (EY).
View Article and Find Full Text PDFRetin Cases Brief Rep
December 2024
Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, USA.
Purpose: To report the clinical presentation, treatment course, and outcome of a case of bilateral frosted branch angiitis (FBA) and neuroretinitis associated with acute Epstein-Barr virus (EBV) infection in a pediatric patient with Turner Syndrome.
Methods: Case report with multimodal ocular imaging and extensive systemic workup.
Results: A 16-year-old female with Turner syndrome presented with acute bilateral vision loss, hearing loss, and ataxia.
Retin Cases Brief Rep
December 2024
Casey Eye Institute, Oregon Health & Science University, Portland, OR.
Purpose: To describe two cases of pediatric patients with Coats disease who developed nerve fiber layer (NFL) schisis.
Methods: Observational case series.
Results: Two male pediatric patients, ages 2 and 14, who were being treated for Coats disease were found to have NFL schisis on optical coherence tomography.
Drug Deliv Transl Res
January 2025
Pharmaceutical Research and Development, Ezequiel Dias Foundation, Rua Conde Pereira Carneiro 80, Gameleira, Belo Horizonte, CEP 30510-010, Minas Gerais, Brazil.
Current treatments for retinal disorders are anti-angiogenic agents, laser photocoagulation, and photodynamic therapies. These conventional treatments focus on reducing abnormal blood vessel formation in the retina, which, in a low-oxygen environment, can lead to harmful proliferation of endothelial cells. This results in dysfunctional, leaky blood vessels that cause retinal edema, hemorrhage, and vision loss.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!